<DOC>
	<DOCNO>NCT00030550</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may effective treatment anemia cause myelodysplastic syndrome . PURPOSE : Randomized phase II trial study effectiveness thalidomide treat anemia patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Thalidomide Treating Anemia Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy thalidomide treatment anemia patient myelodysplastic syndrome . - Determine whether drug reduces frequency leukemia transformation decrease bone marrow blast percentage patient . - Determine effect drug neutrophil platelet production number episode febrile neutropenia patient . - Determine safety drug patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord International Prognostic Scoring System score ( low intermediate-1 v intermediate-2 high ) transfusion dependence ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive oral thalidomide daily week 1-24 . - Arm II : Patients receive oral placebo daily week 1-24 . In arm , patient progress leukemia 24 week therapy may receive open-label thalidomide additional 24 week absence disease progression unacceptable toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A total 220 patient ( 110 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome ( MDS ) least 12 week duration Refractory anemia ( RA ) RA ring sideroblast RA excess blast Chronic myelomonocytic No therapyrelated MDS No myelosclerosis myelofibrosis occupy 30 % marrow space ( assess grade 3+ great ) No transformation acute myeloid leukemia No 20 % blast bone marrow No 5 % blast peripheral blood Patients erythropoietin level 100 mU/mL less must fail epoetin alfa treatment ( i.e. , least 30,000 unit epoetin alfa weekly least 6 week ) Transfusiondependent ( receive least 2 unit pack RBCs whole blood within past 8 week ) OR Transfusionindependent ( pack RBC whole blood transfusion within past 8 week 2 hemoglobin level ( least 7 day apart ) less 11 g/dL ) No iron deficiency ( e.g. , absent bone marrow iron store ) If marrow aspirate evaluable , transferrin saturation must least 20 % ferritin least 50 ng/mL No uncorrected B12 folate deficiency No contributing cause anemia ( e.g. , autoimmune hereditary hemolytic disorder gastrointestinal blood loss ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Zubrod 02 Life expectancy : At least 6 month Hematopoietic : See Disease Characteristics Absolute neutrophil count least 500/mm^3 Hepatic : Bilirubin great 2.0 mg/dL AST ALT less 2 time upper limit normal ( ULN ) Hepatitis B surface antigen negative Hepatitis C negative Renal : Creatinine great 1.5 time ULN Cardiovascular : No uncontrolled hypertension No clinically significant , symptomatic , unstable cardiovascular disease unrelated MDS Pulmonary : No clinically significant , symptomatic , unstable pulmonary disease unrelated MDS Neurologic : No clinically significant , symptomatic , unstable neurologic disease unrelated MDS No history epilepsy No sustained neurologic deficit ( e.g. , stroke ) No grade 2 great peripheral neuropathy Other : Not pregnant nursing Negative pregnancy test Fertile patient must use least 1 highly effective 1 additional effective method contraception 4 week prior , , 4 week study participation HIV negative No clinically significant , symptomatic , unstable endocrine , gastrointestinal , genitourinary disease unrelated MDS No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No lifethreatening active infection require parenteral antibiotic No serious concurrent illness PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics More 7 day since prior hematopoietic growth factor ( e.g. , epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) , interleukin3 ) No prior thalidomide No prior agent intend inhibit vascular endothelial growth factor tumor necrosis factor alfa ( e.g. , etanercept infliximab ) No concurrent epoetin alfa Chemotherapy : No concurrent chemotherapy may active MDS Endocrine therapy : More 30 day since prior androgens No requirement ongoing therapy systemic corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : More 30 day since prior treatment MDS except RBC transfusion epoetin alfa More 30 day since prior participation another experimental clinical trial More 30 day since prior experimental drug No concurrent investigational agent treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
</DOC>